{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T09:01:09Z","timestamp":1791536469474,"version":"4.3.4"},"reference-count":37,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,18]],"date-time":"2021-12-18T00:00:00Z","timestamp":1639785600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002418","name":"Intel Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002418","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","award":["825510"],"award-info":[{"award-number":["825510"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014597","name":"LAM Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014597","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001368","name":"V Foundation for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001368","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000921","name":"European Cooperation in Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["134013-CSDG-19-163-01-TBG"],"award-info":[{"award-number":["134013-CSDG-19-163-01-TBG"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010544","name":"Exelixis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010544","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P50 CA127003"],"award-info":[{"award-number":["P50 CA127003"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014382","name":"Ipsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015686","name":"The Christie Hospital NHS Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015686","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.esmoop.2021.100378","type":"journal-article","created":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T01:31:21Z","timestamp":1642037481000},"page":"100378","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":137,"title":["How I treat biliary tract cancer"],"prefix":"10.1016","volume":"7","author":[{"given":"A.","family":"Lamarca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Edeline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl 5","key":"10.1016\/j.esmoop.2021.100378_bib1","doi-asserted-by":"crossref","first-page":"v28","DOI":"10.1093\/annonc\/mdw324","article-title":"Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Valle","year":"2016","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2021.100378_bib2","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"Suppl 1","key":"10.1016\/j.esmoop.2021.100378_bib3","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/liv.14086","article-title":"Clinical presentation, diagnosis and staging of cholangiocarcinoma","volume":"39","author":"Forner","year":"2019","journal-title":"Liver Int"},{"issue":"1","key":"10.1016\/j.esmoop.2021.100378_bib4","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jhep.2019.01.038","article-title":"18F-fluorodeoxyglucose positron emission tomography (18FDG-PET) for patients with biliary tract cancer: systematic review and meta-analysis","volume":"71","author":"Lamarca","year":"2019","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1016\/j.esmoop.2021.100378_bib5","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","article-title":"Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study","volume":"20","author":"Primrose","year":"2019","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2021.100378_bib6","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1001\/jama.2012.7352","article-title":"Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial","volume":"308","author":"Neoptolemos","year":"2012","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.esmoop.2021.100378_bib7","doi-asserted-by":"crossref","first-page":"101936","DOI":"10.1016\/j.ctrv.2019.101936","article-title":"Current standards and future perspectives in adjuvant treatment for biliary tract cancers","volume":"84","author":"Lamarca","year":"2020","journal-title":"Cancer Treat Rev"},{"issue":"suppl 4","key":"10.1016\/j.esmoop.2021.100378_bib8","first-page":"S260","article-title":"Adjuvant gemcitabine-based chemotherapy for biliary tract cancer: pooled analysis of the BCAT and PRODIGE-12 studies","volume":"31","author":"Edeline","year":"2020","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2021.100378_bib9","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1200\/JCO.18.02178","article-title":"Adjuvant therapy for resected biliary tract cancer: ASCO clinical practice guideline","volume":"37","author":"Shroff","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"16","key":"10.1016\/j.esmoop.2021.100378_bib10","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1200\/JCO.2011.40.5381","article-title":"Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis","volume":"30","author":"Horgan","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"14","key":"10.1016\/j.esmoop.2021.100378_bib11","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.esmoop.2021.100378_bib13","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1200\/JCO.21.00679","article-title":"Modified FOLFIRINOX versus CISGEM chemotherapy for patients with advanced biliary tract cancer (PRODIGE 38 AMEBICA): a randomized phase II Study","volume":"40","author":"Phelip","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2021.100378_bib14","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1001\/jamaoncol.2019.0270","article-title":"Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: a phase 2 clinical trial","volume":"5","author":"Shroff","year":"2019","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2021.100378_bib15","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","article-title":"Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial","volume":"22","author":"Lamarca","year":"2021","journal-title":"Lancet Oncol"},{"issue":"suppl_15","key":"10.1016\/j.esmoop.2021.100378_bib16","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1200\/JCO.2021.39.15_suppl.4006","volume":"39","author":"Yoo","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 15","key":"10.1016\/j.esmoop.2021.100378_bib17","doi-asserted-by":"crossref","first-page":"4603","DOI":"10.1200\/JCO.2020.38.15_suppl.4603","article-title":"A\u00a0randomized phase II study of oxaliplatin\/5-FU (mFOLFOX) versus irinotecan\/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine\/cisplatin chemotherapy","volume":"38","author":"Kim","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2021.100378_bib18","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jhep.2020.03.007","article-title":"Molecular targeted therapies: ready for \u201cprime time\u201d in biliary tract cancer","volume":"73","author":"Lamarca","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"11","key":"10.1016\/j.esmoop.2021.100378_bib19","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group","volume":"31","author":"Mosele","year":"2020","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2021.100378_bib20","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1200\/JCO.2017.75.5009","article-title":"Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma","volume":"36","author":"Javle","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2021.100378_bib21","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"issue":"13","key":"10.1016\/j.esmoop.2021.100378_bib22","doi-asserted-by":"crossref","first-page":"CT010","DOI":"10.1158\/1538-7445.AM2021-CT010","article-title":"Abstract CT010: Primary results of phase 2 FOENIX-CCA2: the irreversible FGFR1-4 inhibitor futibatinib in intrahepatic cholangiocarcinoma (iCCA) with FGFR2 fusions\/rearrangements","volume":"81","author":"Goyal","year":"2021","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.esmoop.2021.100378_bib23","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2021.100378_bib24","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","article-title":"Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial","volume":"7","author":"Zhu","year":"2021","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2021.100378_bib25","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/S1470-2045(20)30321-1","article-title":"Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial","volume":"21","author":"Subbiah","year":"2020","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2021.100378_bib26","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","article-title":"Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials","volume":"21","author":"Hong","year":"2020","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2021.100378_bib27","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/S1470-2045(21)00336-3","article-title":"Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study","volume":"22","author":"Javle","year":"2021","journal-title":"Lancet Oncol"},{"issue":"suppl_3","key":"10.1016\/j.esmoop.2021.100378_bib28","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1200\/JCO.2021.39.3_suppl.320","article-title":"Targeting HER2 (ERBB2) mutation-positive advanced biliary tract cancers with neratinib: results from the phase II SUMMIT \u2018basket\u2019 trial","volume":"39","author":"Harding","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2021.100378_bib29","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol"},{"issue":"26","key":"10.1016\/j.esmoop.2021.100378_bib30","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.esmoop.2021.100378_bib32","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1432-2277.2010.01108.x","article-title":"Liver transplantation for cholangiocarcinoma","volume":"23","author":"Rosen","year":"2010","journal-title":"Transpl Int"},{"issue":"2","key":"10.1016\/j.esmoop.2021.100378_bib33","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/jso.24833","article-title":"Neoadjuvant hyperfractionated chemoradiation and liver transplantation for unresectable perihilar cholangiocarcinoma in Canada","volume":"117","author":"BPT","year":"2018","journal-title":"J\u00a0Surg Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2021.100378_bib34","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/hpb.12082","article-title":"Neoadjuvant chemoradiotherapy followed by liver transplantation for unresectable cholangiocarcinoma: a single-centre national experience","volume":"16","author":"Duignan","year":"2014","journal-title":"HPB (Oxford)"},{"issue":"5","key":"10.1016\/j.esmoop.2021.100378_bib35","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S2468-1253(18)30045-1","article-title":"Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series","volume":"3","author":"Lunsford","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.esmoop.2021.100378_bib36","first-page":"200","article-title":"Advanced intrahepatic cholangiocarcinoma: post hoc analysis of the ABC-01, -02, and -03 clinical trials","volume":"112","author":"Lamarca","year":"2020","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.esmoop.2021.100378_bib37","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1001\/jamaoncol.2019.3702","article-title":"Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma: a phase 2 clinical trial","volume":"6","author":"Edeline","year":"2020","journal-title":"JAMA Oncol"},{"issue":"26","key":"10.1016\/j.esmoop.2021.100378_bib38","doi-asserted-by":"crossref","first-page":"6065","DOI":"10.3748\/wjg.v22.i26.6065","article-title":"Impact of biliary stent-related events in patients diagnosed with advanced pancreatobiliary tumours receiving palliative chemotherapy","volume":"22","author":"Lamarca","year":"2016","journal-title":"World J Gastroenterol"},{"issue":"9","key":"10.1016\/j.esmoop.2021.100378_bib39","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1097\/MPA.0000000000001906","article-title":"Pancreatic enzyme replacement therapy for patients diagnosed with pancreaticobiliary cancer: validation of an algorithm for dose escalation and management","volume":"50","author":"Carnie","year":"2021","journal-title":"Pancreas"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702921003409?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702921003409?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:28:07Z","timestamp":1761856087000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702921003409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S2059702921003409"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2021.100378","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How I treat biliary tract cancer","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2021.100378","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100378"}}